Dynavax Technologies reported $586.49M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adma Biologics ADMA:US USD 34.91M 17.51M
Agenus AGEN:US USD 208.35M 20.03M
Amgen AMGN:US USD 9.5B 4.3B
Astrazeneca AZN:US USD 4.46B 359M
AstraZeneca AZN:LN USD 4.46B 359M
Biogen BIIB:US USD 3.68B 1.03B
Biomarin Pharmaceutical BMRN:US USD 761.52M 141.71M
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Chimerix CMRX:US USD 274.26M 246.18M
Dynavax Technologies DVAX:US USD 586.49M 337.4M
Gilead Sciences GILD:US USD 6.94B 2.2B
Glaxosmithkline GSK:US GBP 3.61B 2.86B
Idera Pharmaceuticals IDRA:US USD 26.8M 2.32M
Minerva Neurosciences NERV:US USD 40.22M 9.53M
Nektar Therapeutics NKTR:US USD 105.76M 28.21M
Neurocrine Biosciences NBIX:US USD 212.2M 48.9M
Novartis NOVN:VX USD 8.73B 5.1B
Regeneron Pharmaceuticals REGN:US USD 3.49B 96.2M
Sarepta Therapeutics SRPT:US USD 1.04B 170.06M
Tg Therapeutics TGTX:US USD 109.86M 37.21M
Vertex Pharmaceuticals VRTX:US USD 9.17B 469.3M